These preclinical results show robust proof-of-concept for HO-1 and Cyp3A11 against NSA-induced liver damage in the Townes model of SCD, paving the way for further development of these compounds as possible new treatments for end-organ damage in SCD. Here, HMOX1 is linked to Schnyder corneal dystrophy.